Neuroendocrine activation after myocardial infarction: Causes and consequences

Heart

Volumn 76, Issue 3 SUPPL. 3, 1996, Pages 53-59

  Cleland, John G F ^a   Cowburn, Peter J ^a   Morgan, Kevin ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; NEUROPEPTIDE Y; NITRIC ACID DERIVATIVE; NORADRENALIN; STREPTOKINASE; VASOPRESSIN;

ADRENERGIC ACTIVITY; HEART ARRHYTHMIA; HEART INFARCTION; HEMODYNAMICS; HUMAN; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 0029911953     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.3_suppl_3.53     Document Type: Review

References (68)

1. McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988;60:117 24.
2. Sigurdsson A, Held P, Swedberg K, Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 1993;126:1068-76.
3. McMurray JJ, Lang CC, MacLean D, McDevitt DG, Struthers AD. Neuroendocrine changes post myocardial infarction: effects of xamoterol. Am Heart J 1990;120: 56-62.
4. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates HR, Werns SW, et al. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol 1991;17:467 73.
5. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390 8.
6. Vaughan DK, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am. J Cardiol 1990;66:529 32.
7. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
8. Broqvist M, Dahlstrom U, Karlberg BE, Karlsson E, Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment, Eur Heart J 1989; 10:1075 83.
9. Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991;65:249 55.
10. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724 9.
11. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994;15:454 61.
12. Omland T, Opstad K, Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J 1994;127:774 9.
13. McCance AJ, Thompson PA, Forfar JC. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J 1993;14:751 7.
14. Fontana F, Bernardi P, Spagnolo N, Capelli M. Plasma atrial natriuretic factor in patients with acute myocardial infarction. Eur Heart J 1990;11:779 87.
15. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993;125: 667-72.
16. Ray SG, McMurray JJ, Morton JJ, Dargic HJ. Circulating endothelin in acute ischaemic syndromes. Br Heart J 1992;67:383-6.
17. Lechleitner P, Genser N, Mair J, Maier J, Artner-Dworzak E., Dienstl F, et al. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem 1993;39: 955-9.
18. Lechleitner P, Genser N, Mair J, Maier J, Artner-Dworzak E, Dienstl F, et al. Endothelin-1 in patients with complicated and uncomplicated myocardial infarction. Clin Invest 1992;70:1070 2.
19. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991;18:38 43.
20. Ray SG, Morton JJ, Dargie HJ. Neuroendocrine activation and markers of early reperfusion in the acute phase of myocardial infarction. Eur Heart J 1993;14:1615 21.
21. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
22. Phillips PA, Sasadeus J, Hodsman GP, Horowitz J, Saltups A, Johnston CI. Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase. Br Heart J 1989;61:139 43.
23. Sigurdsson A, Held P, Swedberg K, Wall B. Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. Eur Heart J 1993;14:1110 7.
24. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109 13.
25. Ngo L, Vesely DL, Bissett JK, Murphy ML, Dinh H, Sallman AL, et al. Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction. Am J Med Sci 1991;301: 157 64.
26. Kettunen RV, Leppaluoto J, Jounela A, Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J 1994;127:1449-55.
27. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-9.
28. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934-42.
29. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 1994; 28:1623-8.
30. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219-26.
31. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995; 95:46-54.
32. Shyu KG, Chen JJ, Shih NL, Chang H, Wang DL, Lien WP, et al. Angiotensinogen gene expression is induced by cyclical mechanical stretch in cultured rat cardiomyocytes. Biochem Biophys Res Commun 1995;211:241-8.
33. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodelling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-92.
34. Whittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation 1991;84: 2123-34.
35. Neuss M, Regitz-Zagrosek V, Hildebrandt A, Fleck E. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation. Biochem Biophys Res Commun 1994; 204:1334-9.
36. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.
37. Michorowski B, Ceremuzynski L. The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J 1983;4:259-64.
38. Batin PD, Hawkins M, Cowley AJ. Patterns of neuroendocrine activation at rest and during exercise following acute myocardial infarction. Eur Heart J 1994;15: 1552-7.
39. Motwani JG, Fenwick MK, McAlpine HM, Kennedy N, Struthers AD. Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. Am J Cardiol 1993;71:281-6.
40. Tomoda H. Atrial natriuretic peptide in acute myocardial infarction. Am J Cardiol 1988;62:1122-3.
41. Robalino BD, Petrella RW, Jubran FY, Bravo EL, Healy BP, Whitlow PL. Atrial natriuretic factor in patients with right ventricular infarction. J Am Coll Cardiol 1990; 15: 546-53.
42. Cleland JG, Oakley CM. Vascular tone in heart failure: the neuroendocrine-therapeutic interface. Br Heart J 1991; 66:264-7.
43. Cleland JG, Dargie HJ. Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int Suppl 1987;20:S220-8.
44. Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JM, Cleland JG. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation 1995;91:2769-74.
45. Cleland JG. ACE inhibitors for myocardial infarction: how should they be used? Eur Heart J 1995;16:153-9.
46. Cleland JG, Gillen G, Dargie HJ. The effects of furosemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J 1988;9:132-41.
47. Cleland JG, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-9.
48. Hirvonen T, Remes J, Mustonen J, Tikkanen I, Tenhunen M, Pyorala K. Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction. Ann Intern Med 1991;23:271-5.
49. Kingma JH, van Gilst WH, Peels CH, Dambrick JH, Verheugt FW, Wielenga RP. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994;15: 898-907.
50. Huttl S, Nussberger J, Lehmann K, Hasford J, Brunner HR, Delius W. Beneficial clinical effect of very early enalapril treatment in patients with acute left ventricular failure complicating myocardial infarction. Clin Cardiol 1995;18:317-23.
51. Omland T, Aarsland T, Aakvaag A, Dickstein K. The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. Int J Cardiol 1993;42:37-45.
52. Bonarjee VV, Omland T, Nilsen DW, Carstensen S, Berning J, Edner M, et al. CONSENSUS II Multi-Echo Study Group. Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. Br Heart J 1995;73:506 10.
53. Pinto YM, van Gilst WH, Kingma JH, Schunkert H. Captopril and Thrombolysis Study Investigators. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1995;25:1622-6.
54. Cleland JG. ACE inhibitors: current understanding and future directions. Br Heart J 1994;72:S1.
55. Dossegger L, Aldor E, Baird MG, Braun S, Cleland JG, Donaldson R, et al. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: a multicentre. double-blind, placebo-controlled trial. Eur Heart J 1993;14 suppl C:18-23.
56. Cleland JGF, Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death? Br Heart J 1994;72:S81 6.
57. Svanegaard J, Angelo-Nielsen K, Pindborg T. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction. Br Heart J 1992;68:38-12.
58. Omland T, Bonarjee VV, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 1995;76:230-5.
59. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
60. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993;72:255 9.
61. Omland T, Bonarjee VV, Nilsen DW, Sundsfjord JA, Lie RT, Thibault G, et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1 98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993;70:409-14.
62. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583 91.
63. Arakawa N, Nakamura N, Aoki H, Moriai N, Suzuki T, Hiramori K. Prognostic value of plasma brain natriuretic peptide concentration in patients with acute myocardial infarction [abstr]. Circulation 1994;90(suppl 1):279.
64. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22.
65. Bonarjee VV, Omland T, Nilsen DW, Caidahl K, Sundsfjord JA, Dickstein K. Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. Br Heart J 1995;73:511-6.
66. Ray SG, Metcalfe MJ, Oldroyd KG, Pye M, Martin W, Christie J, et al. Do radionuclide and echocardiographic techniques give a universal cut off value for left ventricular ejection fraction that can be used to select patients for treatment with ACE inhibitors after myocardial infarction? Br Heart J 1995;73:466-9.
67. Cleland JGF, Ward S, Dutka D, Habib F, Impallomeni M, Morton IJ. Stability of plasma concentrations of N- and C-terminal atrial natriuretic peptides at room temperature. Br Heart J 1996;75:410-3.
68. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DWT, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.